Key facts
- Click Therapeutics’s last known valuation is $600.5M (Apr 2026).
- It has raised $268.4M across 9 recorded rounds; the latest was Early Stage VC ($48.6M) in Mar 2025.
- Notable investors include Revelation Partners, SharesPost, Otsuka Pharmaceutical, Accelmed, Boehringer Ingelheim — 19 tracked in total.
- Click Therapeutics has filed 9 Form Ds with the SEC since 2014, most recently Apr 2025 ($48.6M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 9 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Click Therapeutics
Funding rounds
9 roundsAbout Click Therapeutics
Developer of software as a medical treatment prescription platform designed to deliver safe digital treatments to patients in need. The company's platform personalizes user experiences to drive cognitive and behavioral outcomes, enabling the medical community to optimally treat individuals with brain disorders and neuro-psychiatric dysfunctions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2012
- Employees
- 134
- Website
- clicktherapeutics.com/
- Ownership
- Privately Held (backing)
Click Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Click Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Click Therapeutics in its N-PORT filings yet. We sweep new filings monthly.